OTLK
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Outlook Therapeutics receives FDA approval for LYTENAVA, the first FDA-approved ophthalmic bevacizumab for wet AMDJul 27, 2026
- Outlook Therapeutics received FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA in wet AMDJun 16, 2026
- Outlook Therapeutics wins appeal for ONS-5010/LYTENAVA following formal dispute processMay 26, 2026
- FDA accepted dispute resolution request for ONS-5010/LYTENAVAApr 7, 2026
- Outlook Therapeutics submitted a Type A meeting request to the FDA following receipt of a complete response letterFeb 11, 2026